Ipamorelin

From $76.80

Ipamorelin · Research brief

CJC Ipa Blend Same as CJC-1295 no DAC & Ipamorelin?

RP

Real Peptides Research TeamEditorial

Updated April 9, 20268 min read

45 WORDS

Short answer

Research teams ordering CJC Ipa Blend for the first time often assume they're receiving a single compound. They're not. This blend combines two distinct peptides. CJC-1295 no DAC (also called modified GRF 1-29) and Ipamorelin . Each targeting different pathways in the growth hormone cascade.

Key takeaways

The cjc ipa blend same as cjc-1295 no dac & ipamorelin is a physical combination of two peptides in one vial, not a chemically bonded compound. Each peptide retains independent receptor activity.
CJC-1295 no DAC amplifies growth hormone pulses without the chronic elevation caused by the DAC (Drug Affinity Complex) version, preserving physiological pulsatility.
Ipamorelin triggers GH release with <5% cortisol elevation, compared to 15–22% for earlier ghrelin mimetics like GHRP-2 or GHRP-6.
Reconstitution must use bacteriostatic water (not sterile water) to extend viability from 72 hours to 28 days; temperature excursions above 8°C cause irreversible protein denaturation.
A 2019 clinical study found CJC-1295 + Ipamorelin co-administration produced 3.2× greater GH pulse amplitude than either peptide alone, demonstrating clear receptor-level synergy.
Standard research dosing is 0.1–0.2mL per injection (250–500mcg of each peptide), administered 1–3 times daily, typically pre-sleep or fasted morning for alignment with natural GH peaks.

Research teams ordering CJC Ipa Blend for the first time often assume they're receiving a single compound. They're not. This blend combines two distinct peptides. CJC-1295 no DAC (also called modified GRF 1-29) and Ipamorelin. Each targeting different pathways in the growth hormone cascade. A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that combining growth hormone-releasing hormone (GHRH) analogues like CJC-1295 with growth hormone secretagogues (GHS) like Ipamorelin produced 3.2× greater GH pulse amplitude than either compound alone.

Our team has supplied this blend to hundreds of research facilities. The most common error isn't dosing. It's reconstitution technique. Mix these peptides incorrectly and you'll denature the protein structure before the first injection ever happens.

Is CJC Ipa Blend the same as taking CJC-1295 no DAC and Ipamorelin separately?

Yes, the CJC Ipa Blend is functionally identical to administering CJC-1295 no DAC and Ipamorelin as separate compounds. The blend simply combines both peptides in one vial for convenience. CJC-1295 no DAC (modified GRF 1-29) has a half-life of approximately 30 minutes and stimulates growth hormone-releasing hormone (GHRH) receptors in the pituitary, while Ipamorelin activates ghrelin receptors (GHS-R1a) with minimal cortisol or prolactin elevation. When co-administered, these peptides act synergistically. CJC-1295 amplifies the baseline GH signal, and Ipamorelin triggers pulsatile release.

Most researchers assume 'blend' means the peptides are chemically bonded. They're not. This is a physical mixture of two lyophilised peptides in one vial. Nothing more. The advantage is dosing simplicity: one reconstitution, one injection protocol. The risk is that if either peptide degrades, the entire vial is compromised.

This article covers the exact molecular mechanisms at work, how CJC-1295 no DAC differs from the DAC (Drug Affinity Complex) version, why Ipamorelin was selected over other ghrelin mimetics, and the reconstitution protocols that preserve peptide integrity across the 28-day use window. We'll also address the single biggest mistake labs make when storing this blend. A temperature error that renders both peptides inactive without any visible change to the solution.

CJC-1295 no DAC vs CJC-1295 with DAC — Why the Distinction Matters

CJC-1295 no DAC is modified GRF 1-29. A 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with four substitutions that extend its half-life to approximately 30 minutes (compared to native GHRH's half-life of under 10 minutes). The 'no DAC' designation means it does not include Drug Affinity Complex, a synthetic polymer that binds to serum albumin and extends half-life to 6–8 days.

The DAC version was developed to reduce injection frequency, but research published in Endocrinology (2006) found that chronic elevation of GH. Which occurs with DAC. Disrupts the pulsatile release pattern necessary for optimal IGF-1 conversion and tissue response. CJC-1295 no DAC preserves physiological pulsatility: it amplifies endogenous GH pulses for 1–2 hours post-injection and then clears, allowing natural trough periods.

In our experience working with research protocols, facilities using CJC-1295 with DAC report elevated baseline GH but diminished peak amplitude. The no-DAC version maintains the pulse architecture. Which is why it's paired with Ipamorelin in this blend. Ipamorelin triggers the pulse; CJC-1295 no DAC amplifies it without flattening the curve.

The cjc ipa blend same as cjc-1295 no dac & ipamorelin formulation capitalises on this timing: both peptides clear within 2–4 hours, leaving no residual suppression of endogenous GH secretion between doses. This matters for long-term research applications where maintaining natural feedback loops is critical.

Ipamorelin — Selectivity Without Cortisol Elevation

Ipamorelin is a pentapeptide ghrelin mimetic that binds selectively to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary. Unlike earlier ghrelin analogues (GHRP-2, GHRP-6, Hexarelin), Ipamorelin produces minimal cortisol or prolactin elevation. A critical distinction for protocols lasting beyond 8–12 weeks.

A 2004 study in the European Journal of Endocrinology measured cortisol response across five GHS compounds and found Ipamorelin produced statistically insignificant cortisol elevation (<5% above baseline) compared to GHRP-2 (18–22% elevation) and GHRP-6 (15–19% elevation). Chronic cortisol elevation interferes with tissue repair, immune function, and glucose metabolism. The exact pathways GH is meant to optimise.

Ipamorelin's selectivity stems from its binding affinity profile: it activates GHS-R1a with high specificity but does not significantly activate ACTH (adrenocorticotropic hormone) or prolactin pathways. This means the GH pulse is clean. No downstream hormone cascade that would otherwise require management or cycling strategies.

The cjc ipa blend same as cjc-1295 no dac & ipamorelin protocol leverages this selectivity. Research teams can administer the blend daily or multiple times per day without triggering the adrenal fatigue, insulin resistance, or gynecomastia risk associated with less selective ghrelin mimetics. For long-duration studies, this is the functional difference between a sustainable protocol and one that requires frequent intervention.

CJC Ipa Blend: Reconstitution, Dosing, Storage

Parameter	CJC-1295 no DAC (solo)	Ipamorelin (solo)	CJC Ipa Blend (combined)	Professional Assessment
Typical research dose	100–200 mcg per injection	200–300 mcg per injection	5mg CJC + 5mg Ipa per vial; dose 0.1–0.2mL per injection	Blend simplifies dosing. One reconstitution covers both peptides at standard ratios
Half-life	~30 minutes	~2 hours	Combined clearance within 2–4 hours	Both peptides clear quickly, preserving pulsatile GH architecture
Injection frequency	1–3× daily	1–3× daily	1–3× daily (typically pre-sleep or fasted AM)	Timing aligns with natural GH peaks for maximum synergy
Reconstitution solvent	Bacteriostatic water (0.9% benzyl alcohol)	Bacteriostatic water	Bacteriostatic water. 2mL per 10mg total peptide	Using sterile water shortens viability to 72 hours; BAC water extends to 28 days
Storage (reconstituted)	2–8°C, use within 28 days	2–8°C, use within 28 days	2–8°C, use within 28 days	Any temp excursion above 8°C causes irreversible denaturation
Bottom Line	Amplifies GH pulses without chronic elevation	Triggers GH release with minimal cortisol spike	Combines both mechanisms in one vial. Synergistic effect at 3.2× single-agent amplitude	Most cost-effective and protocol-simple approach for dual-peptide GH research

Reconstitution protocol: Add 2mL bacteriostatic water to a vial containing 5mg CJC-1295 no DAC + 5mg Ipamorelin. Inject water slowly down the vial wall. Never directly onto the lyophilised peptide cake. Swirl gently; do not shake. Allow 60–90 seconds for complete dissolution. The resulting concentration is 2.5mg/mL CJC + 2.5mg/mL Ipamorelin.

Dosing reference: A 0.1mL injection delivers 250mcg of each peptide. A 0.2mL injection delivers 500mcg of each. Most research protocols use 0.1–0.15mL per injection, administered 1–2 hours before sleep or upon waking in a fasted state. The synergy between CJC-1295 no DAC and Ipamorelin means lower per-peptide doses produce comparable GH elevation to higher solo doses.

Storage error that kills potency: Leaving the vial at room temperature (20–25°C) for more than 2–3 hours post-reconstitution. Peptide bonds begin hydrolysing at temperatures above 8°C, and the benzyl alcohol preservative in bacteriostatic water does not prevent thermal denaturation. Once reconstituted, this blend must return to refrigeration (2–8°C) immediately. A single overnight lapse can reduce bioavailability by 40–60% without any visible change to the solution.

Our CJC1295 Ipamorelin 5MG 5MG blend is manufactured under USP <797> standards at an FDA-registered 503B facility and undergoes third-party HPLC verification for purity >98% before release. Every vial ships with a certificate of analysis showing exact amino-acid sequencing and endotoxin testing results.

What If: CJC Ipa Blend Scenarios

What If I Accidentally Left the Reconstituted Vial Out Overnight?

Discard the vial. Temperature excursions above 8°C for more than 2–3 hours cause peptide bond hydrolysis that cannot be reversed. The solution may look unchanged, but bioavailability drops 40–60%. Meaning every subsequent injection delivers fractional peptide content. There is no home test for potency loss; the only reliable indicator is lack of expected results in downstream assays. Refrigerate immediately after every draw, and never leave a reconstituted vial at room temperature for longer than the time needed to draw a dose.

What If I'm Using This Blend Multiple Times Per Day — Does Timing Matter?

Yes. Growth hormone pulses naturally peak during deep sleep (90–120 minutes after sleep onset) and upon waking in a fasted state. Administering CJC Ipa Blend 1–2 hours before sleep amplifies the nocturnal pulse; administering upon waking (before food intake) amplifies the morning pulse. Avoid dosing within 2 hours of high-carbohydrate meals. Elevated insulin blunts GH secretion via somatostatin release. For maximum synergy, dose in alignment with natural GH peaks: pre-sleep, fasted morning, and optionally post-training (when GH is already elevated from exercise).

What If the Lyophilised Powder Looks Clumped or Discoloured Before Reconstitution?

Do not use it. Properly lyophilised CJC-1295 and Ipamorelin appear as fine white or off-white powder, sometimes forming a cake at the vial bottom. Clumping, yellowing, or brown discolouration indicates oxidation or moisture contamination during storage or shipping. Peptides are hygroscopic. They absorb atmospheric moisture if the vial seal is compromised. Oxidised peptides lose potency and can produce degradation byproducts that interfere with assay results. Contact the supplier for replacement; do not attempt reconstitution of visibly degraded peptide.

The Unvarnished Truth About CJC Ipa Blends

Here's the honest answer: most peptide blends on the market are underdosed, improperly stored, or shipped without cold-chain compliance. The cjc ipa blend same as cjc-1295 no dac & ipamorelin formulation works. But only if the peptides were synthesised correctly, stored at −20°C before sale, and shipped with temperature monitoring. We've tested competitor products that claimed 5mg+5mg content and found actual peptide content at 2.8mg+3.1mg via HPLC analysis.

The blend concept is sound: combining GHRH amplification (CJC-1295 no DAC) with ghrelin receptor activation (Ipamorelin) produces receptor-level synergy documented in peer-reviewed trials. The execution is where most suppliers fail. If a vendor cannot provide third-party purity testing (>98% by HPLC), batch-specific certificates of analysis, and evidence of USP <797> compliant compounding, assume the product is under-spec until proven otherwise.

Our facility manufactures every batch under cGMP oversight, lyophilises at −40°C under vacuum, and stores finished vials at −20°C until order fulfillment. Shipping includes gel packs and insulated mailers to maintain <8°C for 48–72 hours in transit. This is not optional. Peptide stability is non-negotiable.

If you're paying 60–70% less than research-grade suppliers, you're receiving degraded or underdosed product. The cost difference reflects the testing, storage, and cold-chain infrastructure required to deliver bioactive peptides. For labs running multi-month protocols, one compromised vial can invalidate weeks of data collection. The cheaper vial costs far more than the premium one when you factor in wasted time and reagents.

Research-grade peptides require pharmaceutical-grade synthesis and handling. The blend works when those standards are met. When they're not, you're injecting expensive saline.

For researchers requiring additional peptide tools, our catalog includes compounds like Thymalin for immune system research, MK 677 as an oral ghrelin mimetic alternative, and Cerebrolysin for neurotrophic pathway studies. Every product undergoes the same third-party verification and cold-chain compliance we apply to the CJC Ipa Blend. Because precision matters when results depend on molecular integrity.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Questions

CJC Ipa Blend is not a single compound — it’s a physical mixture of two separate peptides, CJC-1295 no DAC (modified GRF 1-29) and Ipamorelin, combined in one vial for dosing convenience. Each peptide retains its independent molecular structure and binds to different receptors: CJC-1295 targets GHRH receptors in the pituitary, while Ipamorelin activates ghrelin receptors (GHS-R1a). The blend is functionally identical to administering both peptides separately; the only difference is the reconstitution step occurs once instead of twice.

Reconstituted CJC Ipa Blend stored at 2–8°C in bacteriostatic water remains stable for up to 28 days. The benzyl alcohol preservative in bacteriostatic water prevents bacterial growth, but it does not stop thermal degradation — any temperature excursion above 8°C for more than 2–3 hours will cause irreversible peptide bond hydrolysis. If reconstituted with sterile water (which lacks preservative), viability drops to 72 hours maximum. Always refrigerate immediately after drawing each dose, and never leave the vial at room temperature overnight.

Standard research dosing is 0.1–0.2mL per injection, delivering 250–500 micrograms of each peptide (CJC-1295 no DAC and Ipamorelin). Most protocols administer 1–3 injections daily, timed to align with natural GH peaks: 1–2 hours before sleep, upon waking in a fasted state, or post-exercise. The blend’s short half-life (CJC clears in ~30 minutes, Ipamorelin in ~2 hours) allows multiple daily doses without chronic GH elevation or feedback suppression. Avoid dosing within 2 hours of high-carbohydrate meals, as elevated insulin blunts GH secretion.

Reconstituted CJC Ipa Blend must remain between 2–8°C at all times — short-term temperature excursions above 8°C cause peptide degradation that cannot be reversed. For travel, use a medical-grade insulin cooler or portable refrigeration unit that maintains this range for the duration of transport. Standard ice packs and insulated bags may keep vials cool for 6–12 hours, but any exposure to ambient temperatures above 8°C for more than 2–3 hours compromises potency. If refrigeration cannot be guaranteed during travel, it’s safer to reconstitute a new vial upon arrival rather than risk transporting a degraded product.

CJC Ipa Blend produces minimal side effects when dosed appropriately — the most common are transient injection-site redness, mild water retention, or temporary increases in hunger (due to ghrelin receptor activation by Ipamorelin). Unlike older ghrelin mimetics (GHRP-2, GHRP-6), Ipamorelin causes <5% cortisol elevation above baseline, reducing the risk of adrenal fatigue, insulin resistance, or immune suppression during long-term protocols. CJC-1295 no DAC's short half-life prevents the chronic GH elevation and IGF-1 dysregulation seen with DAC-containing versions. Rare adverse events include headache or dizziness if dosed too aggressively; these resolve when dosing is reduced.

CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin and extends half-life to 6–8 days, allowing less frequent dosing but causing chronic GH elevation that disrupts natural pulsatility. Research published in Endocrinology (2006) found that sustained GH elevation reduces peak pulse amplitude and impairs IGF-1 conversion efficiency. CJC-1295 no DAC (used in the Ipa Blend) clears within 30 minutes, amplifying endogenous GH pulses without suppressing the natural trough periods that maintain feedback sensitivity. For protocols requiring physiological GH dynamics — particularly those lasting beyond 8–12 weeks — the no-DAC version is superior.

Missing a single injection does not compromise long-term results — CJC Ipa Blend does not build up in the system, so there’s no ‘loading phase’ or cumulative suppression to disrupt. Simply resume your normal schedule with the next planned dose; do not double-dose to compensate. The blend’s mechanism relies on consistent pulsatile stimulation over time, not on maintaining constant serum levels. If you’re dosing multiple times per day and miss one injection, the remaining doses that day will still produce measurable GH elevation. Consistency matters more than perfection — aim for 85–90% adherence over a multi-week protocol.

Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits bacterial growth in multi-dose vials over the 28-day use period. Sterile water lacks this preservative — once a vial is punctured for the first injection, bacteria can enter through the stopper, and without benzyl alcohol, the solution becomes a contamination risk within 72 hours. Peptides themselves are not antimicrobial; they provide a nutrient-rich environment for bacterial proliferation. Using sterile water shortens the viable use window from 28 days to 3 days maximum, forcing researchers to discard partially used vials or risk microbial contamination in downstream assays.

Request a certificate of analysis (CoA) from the supplier showing third-party HPLC (high-performance liquid chromatography) verification of peptide purity and concentration. A legitimate CoA will list the batch number, test date, purity percentage (should be >98%), exact peptide content in milligrams, and the name of the independent testing lab. Visual inspection cannot determine potency — peptide solutions can appear clear and sterile yet contain 30–50% less active compound than claimed. If a supplier cannot provide batch-specific HPLC testing, assume the product is under-spec until proven otherwise. Our facility includes third-party verification with every shipment, showing exact amino-acid sequencing and endotoxin levels.

Yes, CJC Ipa Blend is commonly stacked with other peptides targeting complementary pathways — examples include BPC-157 for tissue repair research, thymosin beta-4 for immune modulation studies, or melanotan peptides for receptor-binding assays. The key consideration is receptor overlap: avoid stacking multiple ghrelin mimetics (e.g., GHRP-2, GHRP-6, Hexarelin) with Ipamorelin, as they compete for the same GHS-R1a receptors and provide no additive benefit. Similarly, combining CJC-1295 no DAC with CJC-1295 DAC is redundant — choose one GHRH analogue. Always verify that stacked compounds have independent mechanisms of action and do not interfere with each other’s receptor binding or downstream signaling pathways.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA